Postdoc - Biology (m/f/d)- Universitätsklinikum Tübingen

Universitätsklinikum Tübingen; Tübingen; Vor Ort; EUR 50.000 - 65.000; Vollzeit

Zusammenfassung

A leading academic medical institution in Tübingen is seeking a motivated Postdoctoral Researcher in Gene Therapy of pre-leukemia syndromes. The role involves designing experiments, developing gene editing protocols, and participating in clinical trial preparations. Candidates should have a PhD in cellular/molecular biology and experience with gene editing technologies. The position offers a dynamic research environment with opportunities for professional development.

Leistungen

Access to state-of-the-art facilities

Opportunities for professional development

Subsidy for public transportation tickets

Employee discounts

Qualifikationen

• PhD or postgraduate degree with focus in cellular and molecular biology, gene editing, human stem cell biology, hematopoiesis and leukemogenesis.
• Experience with gene editing technology, HSC culture, and in vivo models of blood cell disorders is highly desirable.
• Experience in GMP production and clinical trial development is desirable.
• Excellent analytical, organizational, and communication skills.
• English proficiency required.

Aufgaben

• Design and conduct in vitro and in vivo experiments using gene-edited hematopoietic stem/progenitor cells.
• Develop and optimize gene editing protocols for therapeutic use.
• Evaluate safety, efficacy, leukemogenicity and off-target effects of gene therapies in preclinical models.
• Participate in the development of GMP-compatible protocols for clinical translation.
• Assist in the preparation of regulatory documents and collaborate with teams for first-in-human trials.

Kenntnisse

Gene editing technology

Human stem cell biology

Cellular and molecular biology

Analytical skills

Communication skills

Ausbildung

PhD or postgraduate degree in relevant field

Jobbeschreibung

About Us

The Faculty of Medicine is one of the four founding faculties of the Eberhard Karls University of Tübingen. With its non-clinical facilities as well as its research and teaching area corresponding to the organisational units of the University Hospital, it is one of the largest medical training and research institutions in Baden-Württemberg.

Division of Translational Oncology

We are seeking a highly motivated and skilled Postdoctoral Researcher to join our interdisciplinary team in the Division of Translational Oncology headed by Prof. Julia Skokowa. Our laboratory is dedicated to advancing the understanding of the molecular mechanisms of hematopoiesis, granulopoiesis, and leukemia development. We also develop innovative gene therapy approaches for hematopoietic stem cell disorders, with the ultimate goal of clinical translation.

Our research focuses on pre-leukemic bone marrow failure syndromes, supported by the integration of the Severe Chronic Neutropenia International Registry (SCNIR), enabling clinically driven translational research. We employ state-of-the-art experimental models to study the pathomechanism of severe congenital neutropenia and Shwachman-Diamond Syndrome as well as the stepwise process of leukemogenic transformation. Our approach integrates gene editing in human and murine primary hematopoietic and iPSC-derived stem cells, in vivo zebrafish and mouse models, multi-omics analyses (e.g., RNA-seq, ATAC-seq, scRNA-seq, scDNA-seq, WES/WGS, targeted NGS, DigiWest), a broad spectrum of molecular and cellular biology techniques, biochemistry and biophysics, computational drug repurposing, and de novo design of novel protein-based therapeutics. Our work also includes developing gene editing strategies to correct or inactivate mutations associated with severe congenital neutropenia, Shwachman-Diamond Syndrome and leukemia.

This position offers the opportunity to contribute to the high-impact project „PHOENIX: Promoting Healing and Overcoming ELANE Neutropenia with Ex Vivo CRISPR-” with a clear translational goal: bringing gene editing of ELANE-mutated severe congenital neutropenia to clinical application, which is based on a gene editing approach recently published by our group (Nasri M, Ritter M et al., Mol Therapy 2024; Skokowa et al., NEJM 2021) and is currently funded by the BMBF/SPARK-BIH program. The postdoc will also participate in the development of gene therapies for other types of congenital neutropenia and other pre-leukemia syndromes.

PostDoc - Gene therapy of preleukemia syndromes (f/m/d)

Department of Internal Medicine, Division of Translational Oncology, index number 6534

Full-time: 100% | Limited: 3 years* | Start of work: 01.10.2025 | Application deadline: 31.08.2025

• Extension is sought

Tasks

• Design and conduct in vitro and in vivo experiments using gene-edited hematopoietic stem/progenitor cells
• Develop and optimize gene editing protocols for ELANE for therapeutic use
• Evaluate safety, efficacy, leukemogenicity and off-target effects of gene therapies in preclinical models
• Actively participate in the development of GMP-compatible protocols for clinical translation
• Assist in the preparation of regulatory documents and collaborate with clinical and regulatory teams to support the transition to first-in-human trials

Profile

• PhD or postgraduate degree with focus in cellular and molecular biology, gene editing, human stem cell biology, hematopoiesis and leukemogenesis
• Experience with gene editing technology, HSC culture, and in vivo models of blood cell disorders is highly desirable
• Experience in GMP production and clinical trial development is desirable
• Excellent analytical, organizational, and communication skills
• English proficiency required

Benefits

• A multicultural, multidisciplinary and highly motivated team
• A dynamic and supportive research environment within a leading academic institution
• Access to state-of-the-art facilities and technologies
• Opportunities for professional development and career advancement, including access to the SPARK-BIH mentoring program and participation at national and international conferences
• Close collaboration with clinical and translational research partners
• Subsidy for public transportation tickets and employee discounts